News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Intraoperative MRI and Adjuvant Radiosurgery


Posted on: 10/16/2002

Citation : 13th Meet World Soc Stereotact Funct Neurosurg, Adelaide 2001.

Stereotact Funct Neurosurg 2001;76:151-158

Intraoperative MRI and Adjuvant Radiosurgery

Author(s): Michael Schulder, Alexander Jacobs, Peter W. Carmel

Abstract :

Introduction: For many patients with brain tumors, the ideal management strategy may be a planned subtotal resection followed by stereotactic radiosurgery (SRS). However, intraoperative visual inspection may be an inadequate measure of the amount of residual lesion. Intraoperative MRI (IMRI) may help to ensure that the goals of surgery have been achieved and that the best possible target for SRS remains.

Patients and Methods: We have operated on 68 patients using the PoleStar N-10 IMRI system (Odin Medical Technologies, Yokne'am, Israel). Benign extraaxial lesions were present in 34 patients. In 12 patients subtotal resection and adjuvant SRS were planned. Diagnoses included 5 pituitary adenomas, 4 meningiomas, 2 vestibular schwannomas, and 1 trigeminal schwannoma. Tumor resection was performed until critical structures (e.g. superior sagittal sinus) were being approached and IMRI demonstrated that the lesion was as small as possible.

Results: In 1 patient a surgical resection was completed, while in 11 others the plan for subtotal resection was carried out. One patient with an extensive meningioma was treated with fractionated 3-dimensional conformal fractionated radiation therapy, as her tumor remained too large for SRS. In the remaining 10 patients an ideally small target remained for SRS; 3 patients have been treated so far.

Conclusions: Adjuvant SRS after subtotal tumor resection is an excellent management strategy for many patients with intracranial tumors. IMRI can ensure that the surgical goals have been reached. Future comparison of target volumes, integral volume doses, and patient outcomes are planned.

Copyright (c) 2002 S. Karger AG, Basel


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740